It is probably worth observing that sometime over the past several years the milestone was undoubtedly passed in which the one millionth person benefited from one or another of our neurofeedback protocols, implemented on one or another of our three generations of neurofeedback systems: NeuroCybernetics, EEGer, and Cygnet. It’s difficult to be too precise about these estimates, in contrast to counting hamburgers at McDonalds! So the estimate is deliberately a conservative one.
If the placebo is such a big deal, why is it not being diligently studied? Why is the ‘cause’ of the placebo ‘effect’ not being looked for? If this is such a huge factor that it governs all drug studies, surely it deserves some attention in its own right.
Years ago an event occurred in Los Angeles that every resident at the time surely remembers. An elderly man plowed through an open-air market in Santa Monica for which a street had been dedicated. There had been no evasive maneuvers, and the man may even have accelerated the vehicle during the encounter. Quite a number of people were killed or injured.
Patty Duke as Neely O’Hara in the 1967 film ‘‘Valley of the Dolls.’’ Credit 20th Century Fox
The death of Patty Duke places the challenge of Bipolar Disorder front and center. In her case, it was not diagnosed for many years, which is not atypical. Her turbulent life even after it was diagnosed testifies to the fact that the condition was not under good control.
In the previous newsletter on this topic we supported the case for cognitive skills training as a sister technology to neurofeedback, and we disparaged the case that the FTC has been making against Lumosity in particular. But how does cognitive skills training actually stack up against neurofeedback? This is a useful discussion to be had.